Bortezomib plus lenalidomide/thalidomide- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: A meta-analysis of randomized controlled trials

Annals of Hematology

Volumn 91, Issue 11, 2012, Pages 1779-1784

  Wang, Anyou ^a   Duan, Qiaohong ^a   Liu, Xin ^a   Ding, Kaiyang ^a   Han, Yongsheng ^a   Zhu, Weibo ^a   Cai, Xiaoyan ^a   Wu, Jingsheng ^a   Sun, Zimin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Lenalidomide; Meta analysis; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MULTIPLE MYELOMA; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; THALIDOMIDE;

EID: 84867337239     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1520-4     Document Type: Article

References (15)

1. Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG (2011) Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol 4(1):51-60
2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516-2520
3. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99(12):4525-4530
4. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101(6):2377-2380
5. Chanan-Khan AA, Giralt S (2010) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28(15):2612-2624
6. Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR et al (2007) Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 25 (31):4933-4937
7. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467-1473
8. National Cancer Institute: Common terminology criteria for adverse events, v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-v3.0
9. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D et al (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134(8):663-694
10. Juni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42-46
11. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376(9758):2075-2085
12. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ et al (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. doi:10.1182/blood-2011-11-395749
13. Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C et al (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118(22):5752-5758
14. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R et al (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28 (34):5101-5109
15. Rosinol L, Cibeira MT, Martinez J, Mateos MV, Oriol A, Terol MJ et al (2009) Thalidomide/Dexamethasone (TD) vs Velcade/Thalidomide/ Dexamethasone (VTD) vs. VBMCP/VBAD/Velcade as induction regimens prior to autologous stem cell transplantation (ASCT): results of a prospective phase III PETHEMA/GEM trial. ASH Ann Meet Abstr 114:130